Vertex's next-generation cystic fibrosis drug gets EU approval

ReutersJul 1, 2025 11:42 AM

July 1 (Reuters) - Vertex VRTX.O said on Tuesday that its next-generation drug, Alyftrek, gained European Commission approval for the treatment of cystic fibrosis.

CF is an inherited disorder resulting from the absence of a specific protein, which disrupts the movement of salt and water in and out of cells in various organs.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

TradingKey - During the US market opening session on May 7, Tesla (TSLA.US) shares extended their rebound momentum, rising more than 2% at one point to open at $406, returning above the $400 level. On May 5 and 6, the stock touched the $400 mark intraday but closed below that threshold on both days.

Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

With a sold-out HBM pipeline, leadership in G9 NAND technology, and a valuation that has yet to fully account for its 2030 trillion-dollar potential, Micron remains a cornerstone "buy" for any long-term tech portfolio.

Gold Price Forecast: U.S.-Iran Tensions Ease, Nonfarm Payrolls Looming, What’s Next for Gold?

TradingKey - After retesting the $4,500 level this Monday, gold prices (XAUUSD) staged a strong recovery of over $200 across Tuesday and Wednesday, breaking above the $4,700 mark. As of press time today (May 7), the gold price maintains its upward momentum, trading at $4,748.77. The $4,800 threshold

WTI and Brent Futures Both Fall Below $100 Mark, Have Oil Prices and Energy Sector Peaked?

TradingKey - WTI crude oil futures settled at $96.21 per barrel on May 6, plummeting 6.3%. This marked the first close below the $100 level in six days and the largest single-day decline since March 17. Brent crude oil futures fell over 7.73% on the same day, intraday breaking below the $100 mark for the first time since April 22.

IONQ First-Quarter Earnings Beat Expectations, Shares Fall After Hours; Is IONQ Still Worth Investing?

TradingKey - IONQ’s latest earnings beat expectations, but shares fell after-hours as the market had previously overextended performance expectations; the medium-to-long-term outlook remains bullish.

Featured Tools